Testosterone Therapy in Men in Their 40s: A Narrative Review of Indications, Outcomes, and Mid-Term Safety

Late-onset testosterone deficiency in early middle-aged men (40-49 years) is increasingly recognized and is often associated with obesity, metabolic syndrome, and sleep apnea. Prevalence estimates suggest that 6%-12% of men in this age group have biochemically low testosterone levels, though variation in diagnostic thresholds, study populations, and assay methods contributes to differing estimates. This narrative review synthesizes current literature on the indications, clinical benefits, and mid-term safety of testosterone replacement therapy (TRT) in men aged 40-49 years. Evidence suggests that TRT offers the greatest benefit in patients with biochemically confirmed hypogonadism, typically defined as total testosterone levels below 300 ng/dL on at least two early-morning measurements (although thresholds vary between 280 and 350 ng/dL, depending on the guideline), in the presence of compatible symptoms. Documented clinical improvements include enhanced sexual function, gains in lean mass, reduction in fat mass, and metabolic benefits such as decreased waist circumference and improved insulin sensitivity, particularly when combined with structured lifestyle interventions. Additional benefits reported in select cohorts include improvements in bone mineral density, mood, energy, vitality, and, to a modest degree, cognition. Safety data, primarily from randomized controlled trials and large observational studies, suggest no significant increase in major adverse cardiovascular events when patients are carefully selected and appropriately monitored. Nonetheless, vigilance is required for erythrocytosis, prostate health, and fertility suppression. Long-acting intramuscular formulations carry the highest risk of hematocrit elevation, highlighting the importance of structured surveillance. Current evidence supports a favorable risk-benefit profile for TRT in appropriately selected men in their 40s. However, important gaps remain regarding long-term, age-specific safety, optimal delivery methods, and precision medicine approaches. Future research should focus on age-stratified trials with extended follow-up to refine patient selection and optimize treatment strategies. In the meantime, individualized decision-making, guided by established clinical practice recommendations and regular monitoring, remains the cornerstone of safe and effective TRT in this demographic.